ROVI to Manufacture New Drug in PTS with Exports to 50 Countries.
Pharmaceutical company Laboratorios ROVI has announced that it will manufacture a new thrombosis drug at its plant in the Granada Health Science Technological Park (PTS). The drug is expected to be exported to more than 50 countries around the world. ROVI made the announcement during a visit by the mayor of Granada, Francisco Cuenca, to the company's facilities.
The new product will help boost the company’s growth in the biosimilars market, currently estimated to be worth up to 1 billion euros in Europe. The new drug is to be used to treat thrombosis and is a biosimilar of enoxaparin sodium. It will be exported to 50 countries worldwide.
On 7 March, ROVI announced that it had received authorisation to market a low molecular weight heparin (biosimilar of enoxaparin sodium) in 26 EU countries.
According to ROVI's CEO, Juan López-Belmonte, “the enoxaparin sodium market is worth more than 1 billion euros in Europe, and this will be a great opportunity for ROVI. It could help us increase our presence in emerging markets, where enoxaparin sodium sales are worth 500 million.”
ROVI will invest 5 million euros in the manufacture of the new drug, creating 20 new jobs. ROVI's Director of Communications, José Eduardo González, said that “from the outset we have been committed to our factory at the Health Science Technological Park. We were the first national company to open facilities here in 2008, and not for nothing.”